These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 9329386

  • 1. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
    Chapman IM, Pescovitz OH, Murphy G, Treep T, Cerchio KA, Krupa D, Gertz B, Polvino WJ, Skiles EH, Pezzoli SS, Thorner MO.
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
    [Abstract] [Full Text] [Related]

  • 2. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
    Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO.
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
    [Abstract] [Full Text] [Related]

  • 3. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [Abstract] [Full Text] [Related]

  • 4. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
    Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
    [Abstract] [Full Text] [Related]

  • 5. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
    Codner E, Cassorla F, Tiulpakov AN, Mericq MV, Avila A, Pescovitz OH, Svensson J, Cerchio K, Krupa D, Gertz BJ, Murphy G.
    Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
    [Abstract] [Full Text] [Related]

  • 6. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
    Van den Berghe G, Wouters P, Carlsson L, Baxter RC, Bouillon R, Bowers CY.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
    [Abstract] [Full Text] [Related]

  • 7. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback.
    Chapman IM, Hartman ML, Pezzoli SS, Harrell FE, Hintz RL, Alberti KG, Thorner MO.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2996-3004. PubMed ID: 9284733
    [Abstract] [Full Text] [Related]

  • 8. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
    Shah N, Evans WS, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
    [Abstract] [Full Text] [Related]

  • 9. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers CY.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [Abstract] [Full Text] [Related]

  • 10. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
    Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ.
    J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
    [Abstract] [Full Text] [Related]

  • 11. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
    Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
    [Abstract] [Full Text] [Related]

  • 12. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
    Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
    [Abstract] [Full Text] [Related]

  • 13. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
    Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO.
    Ann Intern Med; 2008 Nov 04; 149(9):601-11. PubMed ID: 18981485
    [Abstract] [Full Text] [Related]

  • 14. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
    Iranmanesh A, South S, Liem AY, Clemmons D, Thorner MO, Weltman A, Veldhuis JD.
    Eur J Endocrinol; 1998 Jul 04; 139(1):59-71. PubMed ID: 9703380
    [Abstract] [Full Text] [Related]

  • 15. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O, Laughlin GA, Yen SS.
    J Clin Endocrinol Metab; 1997 May 04; 82(5):1472-9. PubMed ID: 9141536
    [Abstract] [Full Text] [Related]

  • 16. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women.
    Anderson SM, Shah N, Evans WS, Patrie JT, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 2001 Feb 04; 86(2):551-60. PubMed ID: 11158008
    [Abstract] [Full Text] [Related]

  • 17. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
    Huhn WC, Hartman ML, Pezzoli SS, Thorner MO.
    J Clin Endocrinol Metab; 1993 May 04; 76(5):1202-8. PubMed ID: 8496311
    [Abstract] [Full Text] [Related]

  • 18. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
    Jacks T, Smith R, Judith F, Schleim K, Frazier E, Chen H, Krupa D, Hora D, Nargund R, Patchett A, Hickey G.
    Endocrinology; 1996 Dec 04; 137(12):5284-9. PubMed ID: 8940347
    [Abstract] [Full Text] [Related]

  • 19. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 04; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 20. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
    Aloi JA, Gertz BJ, Hartman ML, Huhn WC, Pezzoli SS, Wittreich JM, Krupa DA, Thorner MO.
    J Clin Endocrinol Metab; 1994 Oct 04; 79(4):943-9. PubMed ID: 7962302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.